Saturday 17 October 2026
Export ADAG’s income statement to Excel — free account
Adagene Inc. Sponsored ADR
ADAG Healthcare Biotechnology
Adagene Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $7.7 million, up 7,333.0% from fiscal 2024. Insiders bought in the last twelve months.
2.06
0.34
−14.17%
Follow ADAG
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
5.02 | 3.07 | 2.29 | 2.30 |
+8 more quarters Free account |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.99% | 2.36% | 6.83% | 14.94% | |
Debt/Equity |
0.01 | 0.05 | 0.12 | 0.26 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.86) | (0.04) | (0.01) | (0.05) | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(14.87) | (15.67) | (11.13) | (29.73) | |
Working Capital |
106.05 | 52.20 | 36.85 | 49.59 | |
Capital Expenditures |
(0.15) | (0.02) | 0.00 | (0.03) | |
Net Current Asset Value |
88.29 | 34.46 | 36.76 | 49.03 | |
| Other line items | |||||
Quick Ratio |
4.86 | 2.96 | 2.20 | 2.23 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
0.09 | 0.12 | 0.20 | 0.31 | |
Average Payables |
9.45 | 2.99 | 4.06 | 3.95 | |
Average Assets |
117.18 | 97.00 | 100.91 | 120.83 | |
Average Common Equity |
73.02 | 52.95 | 60.35 | 66.81 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates